Journal Article

DKFZ-2020-02198

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Functional precision medicine identifies new therapeutic candidates for medulloblastoma.

Rusert, J. M. ; Juarez, E. F. ; Brabetz, S.DKFZ* ; Jensen, J. ; Garancher, A. ; Chau, L. Q. ; Tacheva-Grigorova, S. K. ; Wahab, S. ; Udaka, Y. T. ; Finlay, D. ; Seker-Cin, H.DKFZ* ; Reardon, B. ; Gröbner, S.DKFZ* ; Serrano, J. ; Ecker, J.DKFZ* ; Qi, L. ; Kogiso, M. ; Du, Y. ; Baxter, P. A. ; Henderson, J. J. ; Berens, M. E. ; Vuori, K. ; Milde, T.DKFZ* ; Cho, Y.-J. ; Li, X.-N. ; Olson, J. M. ; Reyes, I. ; Snuderl, M. ; Wong, T. C. ; Dimmock, D. P. ; Nahas, S. A. ; Malicki, D. ; Crawford, J. R. ; Levy, M. L. ; Van Allen, E. M. ; Pfister, S.DKFZ* ; Tamayo, P. ; Kool, M.DKFZ* ; Mesirov, J. P. ; Wechsler-Reya, R. J.

2020
AACR Philadelphia, Pa.

This record in other databases:  

Please use a persistent id in citations: doi:10.1158/0008-5472.CAN-20-1655

Abstract: Medulloblastoma (MB) is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most MB patients receive similar therapies, including surgery, radiation, and intensive chemotherapy. Although these treatments prolong survival, many patients still die from the disease and survivors suffer severe long-term side effects from therapy. We hypothesize that each MB patient is sensitive to different therapies and that tailoring therapy based on the molecular and cellular characteristics of patient tumors will improve outcomes. To test this, we assembled a panel of orthotopic patient-derived xenografts (PDX) and subjected them to DNA sequencing, gene expression profiling, and high-throughput drug screening. Analysis of DNA sequencing revealed that most MB do not have actionable mutations that point to effective therapies. In contrast, gene expression and drug response data provided valuable information about potential therapies for every tumor. For example, drug screening demonstrated that actinomycin D, which is used for treatment of sarcoma but rarely for MB, was active against PDX representing Group 3 MB, the most aggressive form of the disease. Functional analysis of tumor cells was successfully used in a clinical setting to identify more treatment options than sequencing alone. These studies suggest that it should be possible to move away from a one-size-fits-all approach and begin to treat each patient with therapies that are effective against their specific tumor.

Note: 2020 Dec 1;80(23):5393-5407

---

Contributing Institute(s):

1. B062 Pädiatrische Neuroonkologie (B062)
2. DKTK HD zentral (HD01)
3. KKE Pädiatrische Onkologie (B310)

Research Program(s):

1. 312 - Functional and structural genomics (POF3-312) (POF3-312)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---